Kura Oncology Provides Update on Phase 2 Trial of Tipifarnib in HRAS Mutant Head and Neck Cancer
February 15, 2018 11:00 ET
|
Kura Oncology, Inc.
– Confirmed partial responses observed in five of six evaluable patients with HRAS mutant HNSCC – – Rate of enrollment increasing with three additional patients enrolled in four months – –...
Kura Oncology to Present at the Leerink Partners 7th Annual Global Healthcare Conference
February 08, 2018 07:30 ET
|
Kura Oncology, Inc.
SAN DIEGO, Feb. 08, 2018 (GLOBE NEWSWIRE) -- Kura Oncology, Inc. (Nasdaq:KURA), a clinical-stage biopharmaceutical company focused on the development of precision medicines for oncology, today...
Kura Oncology Added to Nasdaq Biotechnology Index
December 18, 2017 07:30 ET
|
Kura Oncology, Inc.
SAN DIEGO, Dec. 18, 2017 (GLOBE NEWSWIRE) -- Kura Oncology, Inc. (Nasdaq:KURA), a clinical-stage biopharmaceutical company focused on the development of precision medicines for oncology, today...
Kura Oncology Identifies Potential Biomarkers of Activity for Lead Candidate Tipifarnib in Bone Marrow Cancers
December 11, 2017 10:00 ET
|
Kura Oncology, Inc.
CXCR4/CXCR2 expression ratio and bone marrow homing of myeloid cells identified as potential markers for tipifarnib in MDS, AML and CMML CXCL12/CXCR4 pathway a potential therapeutic target of...
Kura Oncology Reports Positive Phase 2 Study of Tipifarnib in Chronic Myelomonocytic Leukemia
December 10, 2017 09:00 ET
|
Kura Oncology, Inc.
– Primary objective met with three objective responses in nine patients with RAS wild-type tumor status (33%), two additional RAS wild-type patients pending best response evaluation – – All nine...
Kura Oncology to Host Investor Day on November 16, 2017
November 09, 2017 16:05 ET
|
Kura Oncology, Inc.
SAN DIEGO, Nov. 09, 2017 (GLOBE NEWSWIRE) -- Kura Oncology, Inc., (Nasdaq:KURA) a clinical-stage biopharmaceutical company focused on the development of precision medicines for oncology, today...
Kura Oncology Reports Third Quarter 2017 Financial Results and Provides Corporate Update
November 07, 2017 16:05 ET
|
Kura Oncology, Inc.
SAN DIEGO, Nov. 07, 2017 (GLOBE NEWSWIRE) -- Kura Oncology, Inc., (Nasdaq:KURA) a clinical-stage biopharmaceutical company focused on the development of precision medicines for oncology, today...
Kura Oncology Announces Upcoming Presentations at American Society of Hematology Annual Meeting
November 01, 2017 16:05 ET
|
Kura Oncology, Inc.
SAN DIEGO, Nov. 01, 2017 (GLOBE NEWSWIRE) -- Kura Oncology, Inc. (Nasdaq:KURA), a clinical-stage biopharmaceutical company focused on the development of precision medicines for oncology, today...
Kura Oncology to Report Third Quarter 2017 Financial Results
October 31, 2017 16:05 ET
|
Kura Oncology, Inc.
SAN DIEGO, Oct. 31, 2017 (GLOBE NEWSWIRE) -- Kura Oncology, Inc. (NASDAQ:KURA), a clinical-stage biopharmaceutical company focused on the development of precision medicines for oncology, today...
Kura Oncology Lead Candidate Tipifarnib Shows Durable Anti-Tumor Activity in HRAS Mutant Head and Neck Cancer in AACR-NCI-EORTC Update
October 27, 2017 10:50 ET
|
Kura Oncology, Inc.
Confirmed partial responses observed in four out of six patients with HRAS mutant HNSCCTipifarnib demonstrates rapid and durable responses, with partial responses observed beyond one...